Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib

Introduction Our patient treated with pembrolizumab and axitinib is one of the longest survivors in Japan on KEYNOTE 426, despite adverse events, including delayed‐onset hepatitis. We herein present a detailed clinical course and short discussion on the case. Case presentation This was a 49‐year‐old...

Full description

Bibliographic Details
Main Authors: Koshiro Nishimoto, Suguru Shirotake, Yu Miyama, Go Kaneko, Kent Kanao, Daisuke Igarashi, Takayuki Takahashi, Yuta Umezawa, Masanori Yasuda, Masafumi Oyama
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:IJU Case Reports
Subjects:
axitinib
KEYNOTE426
metastatic renal cell carcinoma
pembrolizumab
Online Access:https://doi.org/10.1002/iju5.12422

Internet

https://doi.org/10.1002/iju5.12422

Similar Items